- FGFR3-targeting ADC AMB302 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA)
for the treatment of head and neck cancer.
- Having received IND clearance from the FDA last year, AMB302 is being developed as a first-in-class ADC therapy featuring a Topo1 payload.